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Abstract
Cortistatin (CST), a novel hormone originally described in the rat, mouse, and human
cerebral cortex, displays structural and functional similarities to somatostatin (SRIF).
CST binds to all five somatostatin receptors and, differently from SRIF, also binds to
MrgX2, which has recently been identified as its specific receptor. Little is known about
the distribution of CST and MrgX2 in peripheral non-tumour and neoplastic tissues. The
aim of the present study was therefore to determine by immunohistochemistry and mRNA
analysis (RT-PCR) the distribution of CST and MrgX2 in 56 human non-tumour and
108 tumour tissues, with special reference to neuroendocrine tissue types. Despite the high
level of CST mRNA expression in non-tumour and tumour (both neuroendocrine and non-
neuroendocrine) tissues, the presence of immunoreactive CST was confirmed in a subset
of gastroenteropancreatic, parathyroid, and pituitary non-tumour cells only, and showed a
predominantly focal pattern in most neuroendocrine tumours. Co-localization experiments
in the gastroenteropancreatic system demonstrated that the normal CST-producing cells are
δ cells, while in the adenohypophysis no preferential co-localization of CST with any of the
pituitary hormones was observed. MrgX2 mRNA was variably detected in the hypothalamus,
pituitary, thyroid, lung, gastroenteropancreatic tract, testis, and ovary, and was negative in
the cerebral cortex, parathyroid, and adrenal, as well as in a variety of tumour types.
Conversely, immunolocalization of MrgX2 protein was restricted to neurohypophysis and
testis, whilst all tumours analysed were negative. A possible explanation for the discrepancy
between RT-PCR and immunohistochemistry is that MrgX2 protein was widely detected
in blood vessels, scattered lymphocytes, and gastrointestinal ganglia in both normal and
neoplastic samples. The findings demonstrate a selective distribution of CST in normal and
neoplastic neuroendocrine tissues, suggesting that CST might have a broader functional
role than previously assumed, whereas possible autocrine/paracrine actions via its recently
described specific receptor MrgX2 are restricted to selected tissues.
Copyright  2005 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Cortistatin (CST) is a 17-amino acid neuropeptide
recently discovered in rat, mouse, and humans that
exhibits strong structural homology to somatostatin
(SRIF) [1–4]. The human CST gene was mapped to
chromosome 1p36.3–p36.2 and found to contain two
exons separated by a 1 kb intron [3,5].
Two mature products, CST-17 and CST-29, are
generated by a prohormone convertase, the former
being equivalent to murine CST-14, a cyclic peptide
that shares 11 of its 14 amino acid residues with
SRIF-14, responsible for SRIF binding to its receptors
[1,2].
CST-17 and CST-29 bind to all five SRIF receptors
(subtypes 1–5) with an affinity comparable to that
of SRIF-14 [6]. In addition, both CST-14 and CST-
17, but not SRIF-14, are also able to bind the ghre-
lin receptor type 1a (growth hormone secretagogue
receptor — GHS-R1a) [7–9]. SRIF receptors mediate
multiple SRIF activities including neurotransmission,
neuromodulation, regulation of endocrine and exocrine
secretions, and also the inhibition of tumour growth
[10,11]. Since CST mediates several of its effects
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via activation of SRIF receptors, it was assumed to
share the same biological activities as SRIF. However,
CST also exerts a number of distinct biological activ-
ities (increases slow wave sleep, reduces locomotor
activity) and this evidence led to the existence of a
specific CST receptor being postulated [1].
Recently a novel receptor, named MrgX2 and
belonging to a family of coding sequences related to
the Mas1 oncogene, has been identified and found to
possess a high affinity for CST-14 in vitro. MrgX2
has been identified in the small sensory neurons of
the dorsal root ganglia (with a possible role in noci-
ception) and in rare hippocampal neurons, but not in
the cerebral cortex [12], as opposed to CST, which is
expressed by a distinct subset of gamma amino butyric
acid (GABA)-containing cells in the cortex and hip-
pocampus [13].
In tissues other than the central nervous system, CST
has been localized in the human endocrine pancreas
[14], a finding possibly related to the recently reported
[9] capability of CST to inhibit basal insulin secretion
(probably mediated via SRIF receptors), and in the
immune system [15].
Concerning MrgX2 distribution in peripheral tis-
sues, weak immunohistochemical reactivity was orig-
inally reported in endothelial cells and the testis [12],
but no data are available on CST and MrgX2 distri-
bution in other normal and neoplastic tissues to date.
Since a possible role for CST in tumour growth control
has been reported in thyroid [16] and liver [17] carci-
noma cell lines, the aim of the present study was to
analyse CST and MrgX2 distribution in a large series
of human tissues and related tumours (with special
reference to endocrine tumours), to create a map of
tissues expressing this novel hormone and its target
binding sites.
Materials and methods
Tissue samples
A total of 56 non-tumour autopsy or surgical samples
included cerebral cortex (four cases), hypothalamus
(three cases), pituitary gland (four cases), thyroid (five
cases), parathyroid (two cases of hyperplasia), adrenal
gland (two cases), lung (nine cases), stomach (six
cases), ileum (four cases), colon (eight cases), pan-
creas (five cases), ovary (three cases), and testis (one
case). Serial sections from formalin-fixed, paraffin-
embedded material were used for conventional histol-
ogy, immunohistochemistry, and immunofluorescence
studies. An adjacent fragment was snap-frozen and
kept at −80 ◦C until it was processed for molecu-
lar analysis. In addition, a series of neuroendocrine
tumours, for which both fresh frozen and paraffin-
embedded material was available in most cases, were
also studied. These included 73 benign and malig-
nant neuroendocrine tumours from the pancreas (32
cases), lung (five cases), parathyroid (four cases), thy-
roid (seven cases of medullary carcinoma), adrenal
medulla (five cases), pituitary gland (two cases), skin
(ten cases), and gastrointestinal tract (eight cases).
The hormonal status of the neuroendocrine tumours
analysed was confirmed by clinical syndromes, hor-
monal measurements, and immunohistochemical find-
ings. Finally, a total of 35 non-neuroendocrine tumours
from the pancreas (five ductal adenocarcinomas), lung
(three adenocarcinomas and two squamous cell car-
cinomas), thyroid (three follicular adenomas, three
follicular carcinomas, three papillary carcinomas, and
two anaplastic carcinomas), gastrointestinal tract (12
adenocarcinomas), and testis (two seminomas) were
also analysed. The study was performed according to
the standards of the Institutional Ethical Committee
and to the Helsinki Declaration of 1975 as revised in
1983. The Institutional Review Board of our hospi-
tal approved the study. All tissue samples were de-
identified and anonymized by staff not involved in the
study, according to published procedures [18].
Immunohistochemistry (IHC)
A standard manual immunoperoxidase procedure for
cortistatin-17 (CST-17) and MrgX2 was used on
formalin-fixed and paraffin-embedded tissue sections
after microwave heating and endogenous biotin activ-
ity blockade. CST immunostaining was performed
using a commercial rabbit polyclonal antibody to
human CST-17 (Phoenix Pharmaceutical, Belmont,
CA, USA), diluted 1/10 000 and incubated for 1 h
at room temperature. Rabbit polyclonal antibody to
MrgX2 was purchased from LifeSpan (Seattle, WA,
USA), diluted 1/750 and incubated overnight. The
secondary antibody step, incubation with the strep-
tavidin–peroxidase kit (Biogenex, San Ramon, CA,
USA) and diaminobenzidine incubation, followed.
For CST IHC reactions, further amplification with
biotinylated tyramide (diluted 1/15; GenPoint kit,
Dako, Glostrup, Denmark) and a second incubation
with streptavidin were performed. Control experiments
included the omission of the primary antibody in serial
sections or, in the case of CST IHC, pre-absorption of
the primary antibody with a 100-fold excess of CST-
17 (Phoenix Pharmaceutical) or of SRIF-14 (Bachem
Feinchemikalien, AG Bubendorf, Switzerland). Cere-
bral cortex or pancreatic islets [2,14] and human testis
[12] served as positive controls for CST and MrgX2,
respectively.
Co-localization experiments
In double immunofluorescence co-localization exper-
iments on the same slides of human pancreas and
gastrointestinal tissue, the same antibody to CST
(diluted 1/15) used for IHC, a mouse monoclonal
antibody to insulin (diluted 1/40; Biogenex, clone
HB125), or rabbit polyclonal antibodies to glucagon
(pre-diluted; Biogenex) and SRIF (diluted 1/30; Dako)
were employed. A FITC-labelled secondary anti-rabbit
antibody (Sigma Aldrich, Steinheim, Germany) was
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used to reveal the CST immune reaction and TRITC-
labelled anti-mouse secondary antibody (Southern
Biotech Associates, Inc, Birmingham, USA) was used
to reveal insulin. Glucagon and SRIF-producing cells
were revealed by an anti-rabbit biotinylated secondary
antibody (diluted 1/50; Multilink kit, Biogenex) fol-
lowed by a TRITC–avidin incubation step (Sigma
Aldrich). Double immunofluorescence slides were
analysed using an Olympus FV300 confocal micro-
scope (Hamburg, Germany) equipped with a green
helium neon (543 nm) laser, a blue argon (488 nm)
laser, and FluoView 300 software. In double-label
experiments, the two channels were scanned alter-
nately, using only one laser and one detector at any
given time to avoid cross-talk. Cells were imaged
using a 60× oil immersion objective. In the case of
pituitary tissue, CST (diluted 1/10 000), and rabbit
polyclonal antibodies to prolactin and ACTH (both
diluted 1/100; Biogenex), and GH (1/2000; Dako)
were used in a double immunohistochemical proce-
dure, by means of an immunoalkaline phosphatase
(LSAB plus kit, Dako)/Fast red (Biogenex) reaction in
sequence to the standard streptavidin–peroxidase kit.
To avoid interactions between the two immunological
procedures, a treatment with 0.01 N HCl at 37 ◦C, fol-
lowed by prolonged washing, was performed after the
first reaction, as previously described [19].
Molecular analysis of CST and MrgX2 transcripts
The presence of CST and MrgX2 mRNA was inves-
tigated by means of RT-PCR and dot Southern blot
analysis. Total RNA extraction, cDNA transcription,
and PCR amplification of the housekeeping gene (β2
microglobulin) were performed as described elsewhere
[20]. CST primer sequences and PCR conditions have
been reported previously [14]. Primers and probes
used to identify the specific MrgX2 mRNA were
selected according to recently published sequences
[12]. Cranial nerve ganglion and cerebral cortex
mRNA extracts served as positive controls for MrgX2
and CST, respectively. Negative controls included
omission of reverse transcriptase enzyme from the
reverse mixture and of cDNA from the PCR mix-
ture.
The SRIF receptors and GHS-R1a status of most
cases of the current neuroendocrine tumour series have
been reported previously [20–24]. Additional RT-
PCR experiments for SRIF receptors and GHS-R1a
were also performed in selected cases, with special
reference to non-tumour and neoplastic parathyroid
tissue, according to previously published protocols
[20,21].
For both CST and MrgX2 experiments, dot Southern
blot analysis was performed to test the specificity of
the RT-PCR product further, as previously reported for
CST [14].
Results
Cortistatin mRNA and protein expression in
non-tumour tissues
CST mRNA and protein expression in non-tumour tis-
sues, as revealed by RT-PCR and immunohistochem-
istry, is summarized in Table 1.
Concerning RT-PCR data, tissue samples from the
cerebral cortex, hypothalamus, pituitary gland, thyroid,
parathyroid, adrenal gland, ileum, and testis were
positive in all cases investigated. Large intestine and
pancreas were positive in the majority of cases,
whereas a lower rate of expression was detected in
the lung, stomach, and ovary.
Immunolocalization of CST protein was detected in
the cytoplasm of neuronal cells of the cerebral cor-
tex and hypothalamus, as well as in neuroendocrine
Table 1. Expression of CST and its receptor MrgX2 in human non-tumour tissues
CST MrgX2
Tissue RT-PCR IHC RT-PCR IHC∗
Cerebral cortex 4/4 Positive in neuronal cells 0/4 Negative
Hypothalamus 3/3 Positive in neuronal cells 3/3 Negative
Pituitary gland 4/4 Positive in adenohypophysis 1/4 Negative in pituicytes Positive in
single cells of neurohypophysis
Thyroid 5/5 Negative 3/5 Negative
Parathyroid 2/2 Positive in chief cells 0/2 Negative
Adrenal gland 2/2 Negative 0/2 Negative
Lung 6/9 Negative 3/9 Negative
Stomach 4/6 Positive in endocrine cells (δ) 3/6 Negative
Ileum 4/4 Positive in endocrine cells (δ) 2/4 Negative
Colon 7/8 Positive in endocrine cells (δ) 3/8 Negative
Pancreas 4/5 Positive in islet cells (δ) 3/5 Negative
Ovary 2/3 Negative 1/3 Negative
Testis 1/1 Negative 1/1 Positive in tubules
CST = cortistatin; MrgX2 = Mas-related gene X2; RT-PCR = reverse transcriptase-polymerase chain reaction; IHC =
immunohistochemistry.
∗ In all tissues investigated, positive immunostaining was observed in endothelial cells and scattered lymphocytes; in the
gastrointestinal tract, the myenteric plexus also stained positive.
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Figure 1. Single CST-immunoreactive cells in the mucosa of the gastric antrum (a), colon (b), and duodenum (c, d).
Immunoperoxidase. Original magnification: (a) ×200; (b) ×400; (c) ×100; (d) ×600
pituitary cells. Strong positivity was detected in neu-
roendocrine cells of the pancreatic islets and of the
gastrointestinal tract (Figure 1). Co-localization exper-
iments demonstrated that pancreatic and gastrointesti-
nal δ cells represent the main source of CST protein
(Figure 2). In contrast, no preferential co-expression
of CST with pituitary hormones was observed.
Despite positive RT-PCR results, no immunoreac-
tivity for CST was found in the lung, ovary, thy-
roid, testis, and adrenal, neither in neuroendocrine
nor in non-neuroendocrine cell types. Interestingly,
CST peptide was diffusely present in chief cells of
the parathyroid gland, oxyphilic cells being weakly
immunoreactive (Figure 3). No SRIF-immunoreactive
cells were detected in parathyroid tissue samples.
In order to clarify the potential autocrine/paracrine
role of CST in the parathyroid gland, the presence
of SRIF receptor subtypes and MrgX2 (see also
below) and GHS-R1a mRNAs in non-tumour (hyper-
plastic) and neoplastic samples was tested. Neither
non-neoplastic nor neoplastic tissues showed MrgX2
and GHS-R mRNA expression, while SRIF recep-
tor subtypes 1 and 2 (and 3 in a single case of
parathyroid carcinoma) mRNA signal was demon-
strated.
In control experiments, no immunoreactivity was
found in parallel sections stained omitting the primary
antibody or in pre-absorption experiments with an
excess of CST-17 peptide, whereas CST reactivity
was preserved after pre-absorption with an excess of
SRIF-14.
MrgX2 mRNA and protein expression in
non-tumour tissues
MrgX2 mRNA was distributed heterogeneously among
different non-tumour tissues (see Table 1). No specific
MrgX2 mRNA was demonstrated in the cerebral cor-
tex, parathyroid or adrenal gland. Variable amounts of
MrgX2 transcripts were demonstrated in all other tis-
sues, the hypothalamus (3/3 cases), the thyroid (3/5
cases), and the pancreas (3/5 cases) being the most
positive. Tissue localization analysis by immunohis-
tochemistry (see Table 1) detected MrgX2 protein in
scattered neurons of the neurohypophysis (adjacent to
pituicytes in a single case) and in testicular tubules.
No neuroendocrine cells in any site showed MrgX2
immunoreactivity. Conversely, MrgX2 protein was
localized in blood vessels (endothelia), gastrointesti-
nal ganglion cells, and scattered lymphocytes present
in most tissues investigated (Figure 4).
Cortistatin mRNA and peptide expression in
neuroendocrine and non-neuroendocrine tumours
CST peptide and mRNA expression data in neuroen-
docrine tumours are summarized in Table 2. Specific
CST mRNA was detected in all phaeochromocytomas,
parathyroid adenomas, and neuroendocrine tumours
of the lung, as well as in non-functioning pancre-
atic endocrine tumours. A specific signal was found
in the majority of the other neuroendocrine tumours
tested, namely neuroendocrine tumours of the gas-
trointestinal tract; functioning neuroendocrine tumours
J Pathol 2005; 207: 336–345
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Figure 2. Co-localization of CST and other hormones in a pancreatic islet and duodenal mucosa by confocal laser microscopy.
CST (labelled in green) does not co-localize with insulin and glucagon (labelled in red in a and b, respectively) but strongly
co-localizes with SRIF, as revealed by the intense yellow colour (c), in serial sections of a pancreatic islet. Co-localization with
SRIF is also demonstrated in the duodenal mucosa [same cell stained with green — CST (d), red — SRIF (e), and co-localization
by differential interference contrast without (f) or with (g) fluorescence]
of the pancreas (Figure 5), where no specific asso-
ciation was observed in CST-positive tumours with
respect to hormone production; medullary thyroid car-
cinomas; parathyroid carcinomas; and Merkel cell car-
cinomas.
The majority of the neuroendocrine tumours that
contained CST mRNA by RT-PCR were also CST-
positive by immunohistochemistry, with the exception
of parathyroid adenoma and Merkel cell carcinoma,
which showed no immunoreactivity. The immunohis-
tochemical pattern of CST was granular cytoplasmic
and the staining ranged from 5–10% (the predominant
feature) to 90% (in a minority of cases) of tumour
cells, irrespective of the histological pattern or the tis-
sue of origin (Figure 6). No correlation was observed
between CST expression and tumour behaviour.
Concerning putative endocrine precursor lesions,
in two CST-negative medullary thyroid carcinoma
J Pathol 2005; 207: 336–345
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Figure 3. CST and SRIF receptor (sst) expression in parathyroid tissue. CST immunoreactivity in non-tumour hyperplastic
parathyroid tissue (a) and a parathyroid carcinoma (b); mRNA analysis of CST and sst (c) in hyperplastic parathyroid tissue (lanes
1 and 2), parathyroid adenoma (lanes 3 and 4), and parathyroid carcinomas (lanes 5 and 6) determined by RT-PCR. (a, b)
Immunoperoxidase; original magnification ×400. (c) C− = negative control consisting of the omission of cDNA from the PCR
mixture; C+ = positive control for all PCR experiments consisting of pituitary tissue
cases (one associated with MEN2A syndrome and one
sporadic), peritumoural C-cell hyperplasia was also
negative by CST immunohistochemistry. Moreover, in
a case of gastric carcinoid, both the tumour and the
foci of adjacent nodular neuroendocrine cell hyper-
plasia were CST-immunoreactive (Figure 6). In the
non-neuroendocrine tumour group, a weak mRNA
signal was present in most cases, particularly in
adenocarcinomas of the lung, stomach, and colon,
and in follicular tumours of the thyroid. By con-
trast, CST immunohistochemistry failed to demon-
strate immunoreactive cells in any of the non-
neuroendocrine tumours.
MrgX2 mRNA and protein expression in
neuroendocrine tumours
MrgX2 mRNA and protein expression was analysed
in 24 selected neuroendocrine tumour samples (see
Table 2) that showed immunoreactivity for CST, to
correlate the presence of the hormone product with its
putative receptor. MrgX2 mRNA was detected in 8/24
tumours, generally with a weak signal. As observed
in normal tissues (see above), MrgX2 protein local-
ization was restricted to peritumoural blood vessels,
ganglia, and lymphocytes, whereas the neoplastic com-
ponent was negative in all 24 neuroendocrine tumour
samples investigated, as well as in 12 control non-
neuroendocrine tumours (three lung, three pancreatic,
and three gastrointestinal adenocarcinomas; two semi-
nomas; and one papillary thyroid carcinoma).
Discussion
In the present study, we have demonstrated that
endocrine cells of the gastrointestinal tract, the pan-
creas, the pituitary, and parathyroid glands produce
CST. Co-localization experiments showed that in
both gastrointestinal tract and endocrine pancreas, the
majority of neuroendocrine CST-producing cells co-
express SRIF peptide, thus corresponding to δ cells. A
J Pathol 2005; 207: 336–345
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Figure 4. Immunohistochemical localization of MrgX2 protein in gastrointestinal ganglion cells (a) and small blood vessels (b).
In a testicular seminoma (c–e), some peritumoural, partially sclerotic (c, bottom), as opposed to hyaline, tubules (c, top) show
predominantly membrane (d) MrgX2 immunoreactivity. Conversely, in the seminomatous component (e), no tumour cell, but only
intratumoural lymphocytes were CST-positive. Immunoperoxidase. Original magnification: (a, b, d, e) ×400; (c) ×100
Table 2. Expression of CST and its receptor MrgX2 in neuroendocrine tumours of various sites
CST MrgX2
Location Diagnosis Hormonal status RT-PCR IHC RT-PCR IHC
Pancreas NE tumour Insulin 16/17 7/12 2/7 0/7
Gastrin 0/1 0/1 ND ND
Glucagon 2/3 2/2 0/2 0/2
VIP 1/1 1/1 0/1 0/1
LH 1/1 1/1 0/1 0/1
PP 1/1 1/1 1/1 0/1
Somatostatin 1/1 0/1 ND ND
Not functioning 7/7 5/5 2/5 0/5
Stomach NE tumour — 1/1 1/1 0/1 0/1
Duodenum NE tumour Gastrin 0/1 ND ND ND
Ileum NE tumour — 4/4 1/3 1/1 0/1
Colon NE tumour — 1/1 ND ND ND
Appendix NE tumour — 1/1 0/1 ND ND
Lung NE tumour — 5/5 2/3 1/2 0/2
Thyroid Medullary carcinoma Calcitonin 6/7 1/3 0/1 0/1
Parathyroid Adenoma Parathormone 2/2 0/2 ND ND
Carcinoma Parathormone 1/2 1/1 0/1 0/1
Adrenal gland Phaeo Catecholamines 5/5 1/2 1/1 0/1
Skin Merkel cell carcinoma — 9/10 0/3 ND ND
CST = cortistatin; NE = neuroendocrine; Phaeo = phaeochromocytoma; RT-PCR = reverse transcriptase-polymerase chain
reaction; IHC = immunohistochemistry; MrgX2 = Mas-related gene X2; ND = not done.
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Figure 5. CST expression in pancreatic neuroendocrine tumours. Focal CST immunoreactivity in an insulinoma (a) and a
PP-secreting tumour (b). CST-positive pancreatic islets served as an internal control (b, inset). CST mRNA analysis by RT-PCR
in an insulinoma series (c) was positive in all but one case (lane 9). (a, b) Immunoperoxidase. Original magnification: (a, b) ×200;
(b inset) ×100. (c) C− = negative control consisting of the omission of cDNA from the PCR mixture; C+ = positive control
consisting of pituitary gland
slightly decreasing density of CST-positive cells was
observed from the proximal to the distal gastrointesti-
nal tract, in agreement with the distribution of δ cells
[25].
The biological significance of dual expression in
δ cells of CST and SRIF, which share both simi-
larities (all SRIF receptor-mediated actions) and dif-
ferences (CST actions mediated by non-SRIF recep-
tors), remains unclear. The expression of SRIF recep-
tors in neuroendocrine cells of the gastroenteropan-
creatic system has been demonstrated previously
[20] and suggests puzzling circuits of autocrine/para-
crine/endocrine regulation that would be exerted by
either SRIF or CST, as demonstrated by insulin secre-
tion and glucose metabolism at the pancreatic level
[26]. However, as already mentioned, at variance with
SRIF, CST also binds to the ghrelin receptor GHS-
R1a that is widely expressed in the gastroenteropan-
creatic tract, where it mediates endocrine and non-
endocrine actions. This would predict a functional
interplay between the ghrelin system and CST, but
not SRIF. Moreover, the relevance of functional dif-
ferences between CST and SRIF has been emphasized
by the recent cloning of MrgX2, the putative CST-
specific receptor that is recognized by CST but not
SRIF [12]. This discovery requires detailed mapping
of its distribution in different tissues in order to define
its potential biological properties and CST targets bet-
ter. Here, we have demonstrated that although MrgX2
mRNA is widely expressed in peripheral non-tumour
and tumour tissues, its protein expression is selec-
tively restricted to testicular tubules (as also reported
in the original description by Robas et al [12]), to
the widespread vascular and nerve structures, and to
reactive lymphocytes. This latter observation deserves
further studies on the role of the CST/MrgX2 axis in
the immune system, since CST expression has also
been reported in lymphocytes and other immune cell
types [15].
A peculiar and unexpected finding was the pres-
ence of CST peptide (but not SRIF) in parathyroid
chief cells. The possibility that the parathyroid gland
could produce peptide hormones other than parathor-
mone, namely calcitonin, has been recently described
[27]. The presence of SRIF receptors (particularly
subtype 2) correlates with the reported positivity of
some parathyroid tumours on octreotide scintigraphy
[28], although the absence of any biological effect
of octreotide on parathormone secretion has been
reported by others [29,30]. In any case, since neither
MrgX2 nor GHS-R1a was found in normal and neo-
plastic parathyroid tissues, the possibility that CST
plays a role in regulating parathyroid function via
SRIF receptor subtypes (1–3), in either physiological
or pathological conditions, should be considered.
With regard to tumours, scattered CST-immunoreac-
tive cells (but not the corresponding MrgX2 recep-
tor) were found in the majority of gastroenteropan-
creatic neuroendocrine tumours. No preferential asso-
ciation of CST with tumour behaviour or specific
hormone secretion was observed. The possible exis-
tence of CST-secreting neuroendocrine tumours lead-
ing to chronic CST hypersecretion should be vali-
dated by detailed clinical and biochemical monitor-
ing of hormonal parameters. Limited evidence for the
role of CST in tumour growth control has already
been reported [16,17]. Since all immunohistochemi-
cally CST-positive tumours did not contain MrgX2
protein, whereas the expression of SRIF receptors (par-
ticularly SRIF receptors 2, 3, and 5) and/or GHSR-1a
had previously been detected [20–24] in all sam-
ples (at either protein or mRNA level), the actions of
CST were probably mediated by pathways other than
CST/MrgX2 in the tumours investigated.
Concerning CST and MrgX2 mRNA analysis, our
results are in agreement with recently published quan-
titative RT-PCR data showing widespread CST mRNA
expression in peripheral tissues [31]. However, as
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Figure 6. CST expression in a well-differentiated neuroendocrine tumour of the stomach associated with atrophic gastritis
and enterochromaffin-like (ECL)-cell hyperplasia. Tumour cell nests located in the mucosa and deeply infiltrating the muscolaris
mucosae (a, c) were immunoreactive for CST (b, d). At the periphery of the lesion, microscopic foci of nodular neuroendocrine
cell hyperplasia, as revealed by chromogranin A immunohistochemistry (e), were also focally immunoreactive for CST (f). In
the same pictures, adjacent normal glands show single cells reactive for both chromogranin A and CST. (a, c) H&E; (b, d–f)
immunoperoxidase. Original magnification: (a, b) ×100; (c–f) ×400
observed, for example, for MrgX2 protein localiza-
tion in blood vessels, pure mRNA data, especially
when using very sensitive techniques such as quantita-
tive PCR, should be interpreted carefully, and cannot
stand alone without comparative analysis with tis-
sue localization methods (immunohistochemistry or
in situ hybridization). With regard to this, our hetero-
geneous MrgX2 mRNA data on normal tissues may
be related either to different detection thresholds in
different samples (due to different amounts of inter-
spersed positive cells — ie endothelia, lymphocytes
or ganglion cells) or possibly to unrecognized mech-
anisms of modulation of the expression of the recep-
tor.
In conclusion, we have demonstrated that, firstly,
CST is produced by a subset of normal neuroen-
docrine cells, from the pancreas, gastrointestinal tract,
pituitary, and parathyroid; secondly, in the gastroen-
teropancreatic system these cells appear to be predom-
inantly δ cells; thirdly, the CST receptor, MrgX2, is
selectively expressed by neurohypophyseal neurones,
testis, blood vessels, reactive lymphocytes, and gas-
trointestinal ganglia; and fourthly, a consistent number
of neuroendocrine tumours from different sites express
CST focally, but not its receptor MrgX2: possible
autocrine/paracrine CST actions in neoplastic condi-
tions could therefore be mediated by SRIF or ghrelin
receptors.
J Pathol 2005; 207: 336–345
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